In the ever-evolving landscape of healthcare, theranostics stands out as a beacon of hope for cancer patients worldwide.[i] This innovative approach, which combines molecular imaging and targeted radionuclide therapies, is revolutionizing cancer treatment by offering a personalized, precise, and patient-centric method. GE HealthCare is at the forefront of this transformation, leveraging advanced technology to help enhance lives and bring new hope to patients and their families.
Understanding theranostics
Theranostics is a branch of nuclear medicine that uses specific targeting compounds for both diagnostic imaging and therapy. This dual approach allows for a highly personalized treatment plan tailored to the molecular characteristics and clinical history of each patient. By integrating digital and artificial intelligence (AI) solutions, theranostics can potentially provide increased accuracy and efficiency of cancer diagnosis and treatment, moving away from the traditional one-size-fits-all approach.
With over 10 million new cancer cases diagnosed annually,[ii] the need for precision care has never been more urgent. GE HealthCare's commitment to connected, personalized care is helping make a significant impact, offering patients a better quality of life and renewed hope.
Nolan's journey: A testament to theranostics
Nolan Logan's story is a powerful testament to the transformative potential of theranostics. Diagnosed with a neuroendocrine tumor in 2003, Nolan's battle with cancer has been long and arduous. After initial surgery and a decade of remission, his cancer returned, leading him to explore various treatment options, including a targeted internal radiation treatment.
Despite the challenges, Nolan's resilience and the innovative treatments at BAMF Health have significantly improved his quality of life. His experience with radiopharmaceutical therapy has been particularly positive, providing him with comfort and confidence through regular SPECT/CT scans that help monitor the effectiveness of the treatment.
Nolan's journey highlights the importance of cutting-edge care and the profound impact it can have on patients' lives. His renewed energy and optimism are a testament to the advancements in precision care and the dedicated professionals at BAMF Health.
Mike's story: A fight against the odds
Mike's battle with a neuroendocrine tumor began unexpectedly with a kidney stone on Christmas Eve in 2022. The discovery of a fist-sized tumor attached to his pancreas marked the start of a challenging journey. Despite initial setbacks with surgery and chemotherapy, Mike's determination never wavered.
His turning point came with the introduction of a radiopharmaceutical therapy recommended by Dr. Brandon Mancini at BAMF Health. Over the course of four treatments, Mike's tumor shrank significantly, allowing for successful surgical removal. Today, Mike is effectively cancer-free and deeply grateful for the life-saving care he received.
Mike's story underscores the critical role of innovative treatments and the importance of personalized care in achieving positive outcomes. His experience with BAMF Health and the dedicated team of professionals has given him a new lease on life.
The future of cancer care
The stories of Nolan and Mike illustrate the transformative power of theranostics and the promise it holds for the future of cancer care. GE HealthCare's commitment to advancing precision care through cutting-edge technology and personalized treatment monitoring is paving the way for a new era in healthcare.
The demand for theranostics and infrastructure and expanded access to this type of cancer care continues to grow. There is opportunity for reach beyond academic medical centers and larger hospitals into community-based cancer center. It is conservatively estimated by the Society of Nuclear Medicine and Molecular Imaging that the US will need more than 100 theranostics clinics that can treat more than 1,000 patients per year.[iii] Willis Knighton, a community cancer center in Shreveport, Louisiana, represents an example of the growth of theranostics. They recently installed the first GE HealthCare StarGuide SPECT/CT system in the state of Louisiana as part of their Theranostics program. The Cancer Center has undergone a significant expansion that includes the addition of advanced molecular imaging tools to serve patients in Louisiana.
As we continue to explore the potential of theranostics, the focus remains on improving patient outcomes and enhancing the quality of life for those battling cancer. With ongoing advancements and a patient-centric approach, the future of cancer care continues to look brighter.
In conclusion, theranostics represents a significant leap forward in the fight against cancer. By combining advanced technology with personalized care, GE HealthCare is helping to transform lives and bring hope to patients and their families. The inspiring stories of Nolan and Mike are just the beginning, as we look forward to a future where precision care and innovation continue to lead the way in cancer treatment.
[i] Since there is no “typical” hospital/clinical setting and many variables exist, i.e. hospital size, case mix, staff expertise, etc. there can be no guarantee that others will achieve the same results as the individuals described here
[ii] World Health Organization. “Cancer.” https://www.who.int/news-room/fact-sheets/detail/cancer. Published 3 February 2025. Accessed 31 March 2025.
[iii] Society of Nuclear Medicine and Molecular Imaging. How Many Theranostics Centers Will We Need in the United States?. June 2022. Available at: https://jnm.snmjournals.org/content/63/6/805.
